Human hantavirus infections: epidemiology, clinical features, pathogenesis and immunology
Date
2014
Type:
Artículo
item.page.extent
10
item.page.accessRights
Authors
item.contributor.advisor
ORCID:
Journal Title
Journal ISSN
Volume Title
Publisher
EMH Swiss Medical Publishers
item.page.isbn
item.page.issn
item.page.issne
item.page.doiurl
item.page.other
item.page.references
Abstract
In humans, hantaviruses can cause haemorrhagic fever with renal syndrome (HFRS) or hantavirus cardiopulmonary syndrome (HCPS). Currently it is estimated that 150,000 to 200,000 cases of hantavirus disease occur each year, the majority being reported in Asia. However, human hantavirus infections are increasingly reported in the Americas and Europe. Although many of the underlying pathogenic mechanisms still remain unclear, recent evidence rather argues against a purely immune-mediated pathophysiology of human disease. Despite the high morbidity and case-fatality rates of HFRS and HCPS, respectively, no vaccine or drug is currently proven to be preventive or therapeutic. This review summarises clinical features and current epidemiological findings, as well as concepts regarding the immunology, pathogenesis and intervention strategies of human hantaviral diseases.
Description
item.page.coverage.spatial
item.page.sponsorship
Citation
Swiss Med Wkly. 2014 Mar 20;144:w13937
Keywords
hantavirus, HCPS, HFRS, immunology, pathogenesis